Table 2 Urine YKL-40 and NGAL values by baseline characteristics
From: Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients
Clinical characteristics | YKL-40, ng/ml | NGAL, ng/ml | |||
|---|---|---|---|---|---|
N | Median (IQR) | P-value1 | Median (IQR) | P-value1 | |
Pre-existing CKD | |||||
No | 182 | 0.26 (0.08-0.85) | 0.001 | 62 (19–237) | 0.47 |
Yes | 62 | 0.08 (0.03-0.31) | 60 (16–192) | ||
Pre-existing proteinuria | |||||
No | 135 | 0.25 (0.07-0.59) | 0.25 | 49 (16–235) | 0.004 |
Yes | 63 | 0.27 (0.07-2.33) | 125 (44–388) | ||
ACEi/ARB at enrollment | |||||
No | 154 | 0.25 (0.08-1.05) | 0.03 | 92 (24–298) | 0.02 |
Yes | 88 | 0.10 (0.06-0.54) | 42 (17–141) | ||
Hypertension | |||||
No | 77 | 0.21 (0.08-0.68) | 0.66 | 77 (20–249) | 0.58 |
Yes | 171 | 0.18 (0.06-0.97) | 58 (18–234) | ||
Diabetes | |||||
No | 145 | 0.18 (0.05-0.66) | 0.34 | 54 (18–227) | 0.97 |
Yes | 102 | 0.22 (0.07-1.41) | 67 (18–235) | ||
CHF | |||||
No | 154 | 0.27 (0.07-1.41) | 0.02 | 80 (21–336) | 0.05 |
Yes | 92 | 0.13 (0.05-0.54) | 47 (15–141) | ||
CAD | |||||
No | 145 | 0.25 (0.07-0.93) | 0.26 | 99 (27–323) | 0.003 |
Yes | 102 | 0.17 (0.06-0.71) | 41 (14–121) | ||
Stroke | |||||
No | 213 | 0.18 (0.06-0.81) | 0.28 | 54 (19–210) | 0.43 |
Yes | 34 | 0.24 (0.06-2.63) | 102 (15–365) | ||
Liver failure/Cirrhosis | |||||
No | 222 | 0.18 (0.06-0.82) | 0.26 | 53 (18–187) | 0.04 |
Yes | 27 | 0.30 (0.10-1.05) | 237 (21–791) | ||
Active cancer | |||||
No | 188 | 0.17 (0.06-0.63) | 0.07 | 44 (14–165) | 0.001 |
Yes | 60 | 0.29 (0.06-2.48) | 164 (44–416) | ||